FIGURE 2.

Durable partial response with avelumab. Computed tomography scans of a 68‐year‐old male patient with MCPyV+ metastatic Merkel cell carcinoma (A) with disease progression after treatment with chemotherapy (May 2017), (B) who subsequently achieved a partial response after 6 months of avelumab treatment (October 2017), which was maintained after (C) 15 months (August 2018) and (D) 27 months of avelumab treatment (July 2019). Treatment was stopped in September 2019, and the patient had an ongoing partial response with no evidence of recurrent disease at the last follow‐up (January 2020). Images were provided by Prof Samimi. MCPyV+, Merkel cell polyomavirus positive